Advertisement
Valeant
Subscribe to Valeant

The Lead

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.             

Pershing Files Documents for Special Meeting Aimed at Ousting Allergan Directors

July 7, 2014 3:05 pm | by The Canadian Press | News | Comments

Pershing Square Capital Management has formally asked Allergan shareholders to support its bid...

Pershing Square Settles Lawsuit with Allergan

June 27, 2014 3:28 pm | by The Associated Press | News | Comments

Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it...

Allergan Board of Directors Rejects Unsolicited Exchange Offer from Valeant

June 23, 2014 8:23 am | News | Comments

Allergan, announced that its Board of Directors, after consultation with its independent...

View Sample

FREE Email Newsletter

Akorn Divests ECR Pharmaceuticals to Valeant

June 23, 2014 8:18 am | News | Comments

Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal.

Ackman Seeks Allergan 'Poison Pill' End Run

June 13, 2014 8:14 am | News | Comments

Bill Ackman's Pershing Square Capital Management, seeking legal cover in its $53 billion takeover bid for Allergan, filed a lawsuit to confirm that its push for a special meeting of shareholders won't trigger a defensive "poison pill" plan from the Botox maker.

Valeant Plans Hostile Bid for Allergan

June 10, 2014 5:31 pm | by Tom Murphy - AP Business Writer - Associated Press | News | Comments

Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion. Valeant said Tuesday that it looked forward to giving shareholders the opportunity "to speak for themselves" after Allergan Chairman and CEO David Pyott said that the offer wasn't worth discussing in a letter to his Valeant counterpart, Michael Pearson.

Advertisement

Allergan Board Unanimously Rejects Revised Unsolicited Proposal from Valeant

June 10, 2014 8:33 am | News | Comments

Allergan announced that its Board of Directors has unanimously determined that the revised unsolicited proposal from Valeant Pharmaceuticals substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders.

FDA Oks Valeant Toenail Fungus Treatment Jublia

June 9, 2014 7:26 am | by The Associated Press | News | Comments

The Food and Drug Administration has approved a toenail fungus treatment from Valeant Pharmaceuticals International Inc. that could reach $800 million in peak U.S. sales, according to the Canadian drugmaker.        

Proxy Fight Looms in Allergan-Valeant Dispute

June 2, 2014 3:42 pm | News | Comments

Activist investor Bill Ackman said Monday that he will move to replace most of Allergan's board of directors as part of a continuing battle for control of the company.              

Valeant Sweetens Offer for Allergan Again

May 30, 2014 4:01 pm | by ALEX VEIGA, AP Business Writer | News | Comments

Valeant Pharmaceuticals is sweetening its offer to buy Botox maker Allergan for the second time this week. The Canadian drugmaker said Friday it is now offering $72 and a portion of its stock for each Allergan share.      

Nestle to Pay $1.4B for Skin Treatments

May 28, 2014 8:28 am | News | Comments

Nestle says it is paying $1.4 billion in cash for the rights to sell lip and wrinkle treatment Restylane and other skin products in the U.S. and Canada.                

Advertisement

Valeant Raises Cash-Stock Offer for Allergan

May 28, 2014 7:29 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals is adding more cash to its offer to buy Botox maker Allergan in a bid that could now be worth more than $49 billion. The Canadian drugmaker says it will now offer $58.30 and a portion of its stock for each Allergan share.

Valeant to Improve its Hostile Takeover Bid for Allergan

May 13, 2014 9:45 am | by The Canadian Press | News | Comments

Valeant Pharmaceuticals International says it will improve its bid of almost $47 billion for Botox-maker Allergan after the company rejected its hostile takeover offer. Valeant CEO Michael Pearson says the company is prepared to pay a fair price, but will remain financially disciplined when it makes its new offer later this month.

Valeant Pharmaceuticals Enters Into Patent Settlement Agreements with Actavis

May 13, 2014 8:20 am | News | Comments

Valeant Pharmaceuticals International announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya Gel, 1.2%/2.5%, and Tiazac XC.   

Allergan Board Turns Down Valeant Takeover Offer

May 12, 2014 8:17 am | News | Comments

Allergan spurned a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and carries significant risk.                     

Valeant Posts First Quarter Net Loss but Revenues Jump 77%

May 8, 2014 8:10 am | by The Canadian Press | News | Comments

Valeant says the loss includes restructuring, integration and other charges of $135 million primarily related to the acquisition of eyecare company Bausch + Lomb last year.              

Advertisement

Allergan Lifts 2014 Outlook After First Quarter Income Rises

May 7, 2014 11:31 am | by The Associated Press | News | Comments

Botox maker Allergan raised its outlook for the year Wednesday after topping expectations for the first quarter. Executives did not discuss a $45.6 billion offer last month from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to buy the company, but did reiterate that that the proposal is under review.

Valeant Could Be Pushed to Boost Allergan Price By Up to 40%: Analyst

April 29, 2014 8:19 am | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals International could be pushed to increase the cash component of its bid for Botox maker Allergan by up to 40 per cent, an industry analyst said Monday.             

Valeant to Replace Three Board Members; Allergan Adopts Poison Pill Defense

April 23, 2014 2:24 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals International says three of its directors will not stand for re-election this year as it pursues the acquisition of Botox maker Allergan, which has adopted a "poison pill" defense while it considers the offer.   

Valeant, Ackman Bid For Maker of Botox

April 23, 2014 8:37 am | Videos | Comments

WSJ discusses the Ackman/Valeant deal for Allergan.                                  

Investor Pressure Pushing Pharmaceutical M&A Deals

April 22, 2014 7:31 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Allergan Draws Bid from Valeant

April 22, 2014 12:29 am | by Ken Sweet - AP Business Writers - Associated Press | News | Comments

Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.   

Bausch and Lomb Acquisition Proving Profitable for Valeant

February 27, 2014 3:51 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals is seeing more clearly the merits of its acquisition last summer of eye care company Bausch and Lomb and remains on the hunt for another big acquisition this year.                                

Valeant Buying PreCision Dermatology for $475M

February 3, 2014 1:29 pm | News | Comments

Valeant Pharmaceuticals is looking to expand its skin care business by buying PreCision Dermatology for $475 million. Cumberland, R.I.-based PreCision Dermatology makes treatments for skin ailments such as acne and atopic dermatitis, an itchy, chronic skin inflammation.

FDA Approves Retin-A Microsphere 0.08%

January 31, 2014 9:04 am | News | Comments

Valeant Pharmaceuticals International, Inc. announced today that it has received approval from the Food and Drug Administration (FDA) for its  Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris.

Valeant Pharma Approves $1.5B Securities Buyback

January 22, 2014 11:15 am | by The Associated Press | News | Comments

Canadian drugmaker Valeant Pharmaceuticals said Wednesday it will buy back up to $1.5 billion in shares, debt, and other securities. Valeant said it started the new repurchase program in November. The board authorized the company to repurchase convertible notes, senior notes, shares, and other debt or shares.

Valeant Expects to Make More Acquisitions in 2014

January 7, 2014 1:34 pm | by The Canadian Press | News | Comments

Valeant says it is looking for a big acquisition this year and is aiming to be one of the top five pharma companies in the world by the end of 2016. The Quebec-based company says its goal is to have a market capitalization of $150 billion in two years, meaning it would have to more than triple its current value.

Valeant Pharmaceuticals to Acquire Solta Medical

December 16, 2013 8:11 am | News | Comments

Valeant Pharmaceuticals International has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Solta Medical, Inc. for $2.92 per share in cash, which represents a 40% premium to Solta's closing share price on December 13, 2013, the last trading day prior to announcement, or a transaction value of approximately $250 million.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading